Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQR309 in Relapsed/Refractory PCNSL
NCT02669511Phase 2Completed
- Sponsor
- PIQUR Therapeutics AG
- Start
- Nov 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of bimiralisib in primary central nervous system lymphoma (PCNSL), sponsored by PIQUR Therapeutics AG. Primary endpoint: Overall Response Rate. Started Nov 2015; status: completed.
02
Drugs
bimiralisib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT02669511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669511.